GILD News and Press, Gilead Sciences Inc.

2024-07-04 11:30:00 ET Summary This article will present an in-depth analysis of drugs being developed to combat obesity and related diseases. Pharmaceutical companies are highly interested in the global obesity treatment market, which is expected to exceed $100 billion by 2030. ...

2024-07-01 23:57:12 ET Summary Morningstar published 10 Best Value Stocks to Buy for the Long Term, undervalued blue-chip stocks with low price to fair value. Valuation and future return of each stock analyzed, compared to the S&P 500, Bristol-Myers has the highest potential r...

NORTHAMPTON, MA / ACCESSWIRE / July 1, 2024 / Jim Candler had a successful 40-year career in system operations before coming to Gilead three years ago to bring his tech expertise to the Human Resources team. "I was hired at 71 years old. What does that say about Gilead?" says Jim, Senior Direct...

2024-07-01 06:50:00 ET Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments. Three Motley Fool contributors think they've found magnificent stocks retir...

2024-06-30 20:30:56 ET Rounding out the top five were Moderna ( NASDAQ: MRNA ) and Novo Nordisk ( NVO ) with gains of, respectively, ~12.5% and ~11.9% .... Read the full article on Seeking Alpha For further details see: Alnylam, Lilly, AstraZeneca among best ...

2024-06-29 15:44:55 ET More on Eli Lilly, Novo Nordisk, etc. Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis) Eli Lilly: The Party Is Probably Nearing The End ...

2024-06-24 13:00:04 ET Michael Yee from Jefferies issued a price target of $85.00 for GILD on 2024-06-24 10:57:00. The adjusted price target was set to $85.00. At the time of the announcement, GILD was trading at $71.24. The overall price target consensus is at $80.71 wi...

2024-06-24 12:30:03 ET Jefferies analyst issues BUY recommendation for GILD on June 24, 2024 10:57AM ET. The previous analyst recommendation was Buy. GILD was trading at $71.235 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...

2024-06-24 09:41:40 ET Summary Gilead Sciences reported positive Phase 3 data for lenacapavir, a biannual HIV PrEP therapy, leading to a 12% stock boost. Q1 earnings showed growth in HIV product sales, with Trodelvy's notable 39% increase, and total revenue beating estimates by $3...

2024-06-23 12:49:01 ET More on the markets SPY: The Upside Is Likely Capped SPY: Rating Downgrade Due To Overvaluation Perfect Time For November Election Protection S&P posts three-week win streak, but momentum stalls after hitting 5,500 points mark ...